Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing

TALPHERA, INC.

Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.
Cash and investments $21.1M as of March 31, 2026.
Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.
NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.
Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TALPHERA, INC. reported the three months ended March 31, 2026 results: net income $2.6 million, EPS $0.04 per basic and diluted share.

Period: the three months ended March 31, 2026
Net income: $2.6 million
EPS: $0.04 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss attributable to common shareholders for the first quarter of 2026 was $2.6 million, or $0.04 per basic and diluted share

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-016724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.